#USA #New York #Class Action #Pomerantz #NowRx

Class Action Lawsuit Filed Against NowRx, Inc.

On January 22, 2026, Pomerantz LLP declared that a class action lawsuit has been initiated against NowRx, Inc., a company known for its innovative pharmacy solution services. This announcement is particularly important for investors who have experienced financial losses during their involvement with the company's securities. The firm is reaching out to those affected to inform them about the lawsuit and encourage them to get in touch to discuss their potential claims.

Key Details of the Lawsuit

The lawsuit revolves around allegations that NowRx and some of its executives may have engaged in securities fraud and other unlawful business practices. Investors who acquired NowRx securities are advised to contact Pomerantz to explore their options, including the possibility of becoming a lead plaintiff in the ongoing case. The deadline for joining the class action is January 23, 2026. Those interested can reach out via email or phone and are encouraged to provide their contact details and the number of shares they purchased.

Allegations Against NowRx

The core accusations of the lawsuit highlight a series of undisclosed adverse facts regarding NowRx's financial status. Key points raised include:

1. Failure to Disclose Financial Woes: The lawsuit claims that NowRx had not revealed critical information about its dire financial condition, which could have influenced investors' decisions.

2. Imminent Bankruptcy: It is alleged that NowRx was on the verge of bankruptcy or insolvency, a fact that was concealed from investors.

3. Exploratory Sale or Fundraising: The company had supposedly enlisted an investment bank to either explore a sale or to raise significant funds, raising doubts about its operational viability.

4. Valuation Discrepancies: According to the lawsuit, by December 31, 2021, NowRx was valued at only $3.55 per share by an investment bank—this is in stark contrast to the $10.50 share price it sought in its Series C stock offering in 2022.

5. Investment Risks: Consequently, the lawsuit expresses that investors who participated in the Series C stock offering may face significant financial setbacks.

About Pomerantz LLP

Pomerantz LLP, a reputable law firm headquartered in New York with offices across major cities including Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized as a leader in corporate, securities, and antitrust class litigation. Founded over 85 years ago by Abraham L. Pomerantz, the firm has a legacy of advocating on behalf of victims of securities fraud and has successfully secured billions in damages for investors. Their commitment to fighting corporate misconduct is evident in their longstanding track record.

Investors affected by this situation are encouraged to stay informed about their rights and options in the wake of this lawsuit. For more details, interested parties should visit Pomerantz's official website at www.pomerantzlaw.com, where they can also access important documentation related to the case.

As the class action progresses, potential developments will be of significant interest to those who have invested in NowRx, ensuring that affected investors are well-prepared to take action.

Contact Information

For direct inquiries, investors can reach out to Danielle Peyton at Pomerantz LLP through [email protected] or by dialing 646-581-9980, extension 7980. This strong communication channel will assist in addressing any questions and concerns surrounding the class action suit, allowing investors to navigate this complex situation more effectively.